Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $1,163 from $1,168 and keeps a Buy rating on the shares after updating the firm’s model ahead of Q1 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Artelo Biosciences Soars 230% on Obesity Push — Why Is ARTL Stock Now Crashing?
- Insilico announces global R&D collaboration with Eli Lilly worth up to $2.75B
- Eli Lilly announces Taltz, Zepbound met primary, secondary endpoints
- AI Models Split on Eli Lilly (LLY) as Growth Strength Collides With Premium Valuation
- Morning News Wrap-Up: 3/27/26: Today’s Biggest Stock Market Stories